Fumaric acid esters for severe psoriasis: The Leicestershire experience [3]

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 843-844

  Sladden, M J ^a   Osborne, J E ^a   Hutchinson, P E ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; FUMARIC ACID; FUMARIC ACID ESTER; INFLIXIMAB; METHOTREXATE; UNCLASSIFIED DRUG;

DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; LETTER; LYMPHOCYTOPENIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS;

ADULT; DERMATOLOGIC AGENTS; FEMALE; FUMARATES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748444755     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07435.x     Document Type: Letter

References (6)

1. Mrowietz U, Christophers E, Altmeyer P, and the participants in the German Multicentre Study. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol 1998; 138:456-60.
2. Litjens NHR, Nibbering PH, Barrois AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with down-regulation of type 1 cytokines. Br J Dermatol 2003; 148:444-51.
3. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149:363-9.
4. Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004; 150:630-2.
5. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150:741-6.
6. Harries MJ, Chalmers RJG, Griffiths CEM. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 2005; 153:549-51.